Vulvar eccrine porocarcinoma

Summary

Vulvar eccrine porocarcinoma (MONDO:0004281) is a disease. A subtype of vulvar eccrine adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vulvar eccrine porocarcinoma
Mondo ID	MONDO:0004281
DOID	DOID:7565
NCIT	C40306
UMLS	C1520081
MedGen	275616
GARD	0023910
Anatomy (UBERON)	UBERON:0000997
Is cancer (heuristic)	no

Also known as: eccrine porocarcinoma of mammalian vulva · mammalian vulva eccrine porocarcinoma · vulvar eccrine porocarcinoma

Disease family

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm › epidermal appendage tumor › sweat gland neoplasm › eccrine sweat gland neoplasm › eccrine sweat gland cancer › eccrine carcinoma › vulvar eccrine adenocarcinoma › vulvar eccrine porocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.